Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
Researchers at Washington University School of Medicine in St. Louis have identified a pathway involved in harming rods and cones and have found a way to halt that damage.
Combinations of Food and Drug Administration-approved drugs protect against the loss of cells required for vision in a mouse model of blinding retinal diseases.
NEI research fellow Nathan Hotaling, PhD, has been awarded a $65,000 grant from the Knights Templar Eye Foundation to develop a stem cell-based system to study Best disease, a genetic disorder that can cause progressive vision loss.
A pain medicine that potently activates a receptor vital to a healthy retina appears to help preserve vision in an animal model of severe retinal degeneration, NEI-funded scientists at Medical College of Georgia at Augusta University report.
Retinas from our earliest vertebrate ancestors had cone-like photoreceptors, presumably allowing them to see in daylight, but little ability to see at night.
In a study of nearly 650 people with the eye disease age-related macular degeneration (AMD), half still had vision 20/40 or better after five years of treatment with anti-VEGF drugs that are injected into the eye.